{
  "responseHeader":{
    "status":0,
    "QTime":151},
  "response":{"numFound":1,"start":0,"content":"050","docs":[
    {
      "primary_key":"P-047441/00-05",
      "sku":"P-047441/00-05",
      "_id":"P-047441/00-05",
      "ref":"P-047441/00-05",
      "verifyid":"RENZSRGBPIFKKXEFDDNYQLWHBAJVSBJTMZBPERRB",
      "doc_ref":"P-047441",
      "preview":"0",
      "order":6,
      "id":76248619,
      "genre":11,
      "copyright_json":{"year":"2020","holders":{"DE":["Europäische Union"],"EN":["European Union"],"FR":["Union européenne"]}},
      "genreparent":11,
      "status_json":{"shortcut":"PROD","id":586,"titles":{"DE":"IM VERTRIEB","EN":"IN DISTRIBUTION","FR":"EN DIFFUSION"}},
      "titles_json":{
        "EN":"Press conference of Margrethe Vestager, Executive Vice-President of the European Commission, on an antitrust case: Commission fined Teva and Cephalon for delaying entry of cheaper generic medicine",
        "FR":"Conférence de presse de Margrethe Vestager, vice-présidente exécutive de la Commission européenne, sur un cas de pratique anti-concurrentielle : la Commission a infligé des amendes à Teva et à Cephalon pour avoir retardé l&#39;entrée sur le marché d&#39;un médicament générique moins cher"},
      "summary_json":{"FR":"Margrethe Vestager","EN":"Margrethe Vestager"},
      "legend_json":{
        "EN":"<p>On 26 November 2020, Margrethe Vestager, Executive Vice-President of the European Commission in charge of Europe fit for the Digital Age, and Commissioner for Competition, gave a press conference on an antitrust case.  </p><p>The European Commission has fined the pharmaceutical companies Teva and Cephalon €60.5 million for agreeing to delay for several years the market entry of a cheaper generic version of Cephalon&#39;s drug for sleep disorders, modafinil, after Cephalon&#39;s main patents had expired. The agreement was concluded well before Cephalon became a subsidiary of Teva. The agreement violated EU antitrust rules and caused substantial harm to EU patients and healthcare systems by keeping prices high for modafinil.</p>",
        "FR":"<p>Le 26 novembre 2020, Margrethe Vestager, vice-présidente exécutive de la Commission européenne chargée d&#39;une Europe adaptée à l&#39;ère du numérique, et commissaire à la Concurrence, a donné une conférence de presse sur un cas de pratique anti-concurrentielle.</p><p>La Commission européenne a infligé des amendes de 60.5 millions d&#39;euros aux entreprises pharmaceutiques Teva et Cephalon pour s&#39;être mises d&#39;accord pour retarder l&#39;entrée sur le marché d&#39;une version générique moins chère du médicament de Cephalon traitant les troubles du sommeil, le modafinil, après l&#39;expiration des principaux brevets de Cephalon. L&#39;accord a été conclu bien avant que Cephalon ne devienne une filiale de Teva. L&#39;accord a violé les règles de l&#39;UE en matière d&#39;ententes et d&#39;abus de position dominante et a causé un préjudice considérable aux patients et aux systèmes de soins de santé de l&#39;UE en maintenant les prix élevés pour le modafinil.</p>"},
      "project_json":{"value":{"EN":"Press conference of Margrethe Vestager, Executive Vice-President of the European Commission, on an antitrust case: Commission fines Teva and Cephalon \u20AC60.5 million for delaying entry of cheaper generic medicine","FR":"Conférence de presse de Margrethe Vestager, vice-présidente exécutive de la Commission européenne, sur un cas de pratique anti-concurrentielle : CE inflige des amendes de \u20AC60.5 millions à Teva et à Cephalon pour avoir retardé l&#39;entrée sur le marché d&#39;un médicament générique moins cher"},"id":"59351"},
      "search_date":"2020-11-26T05:11:00Z",
      "time":"202011260000",
      "type":"PHOTO",
      "newsphoto":"Y",
      "shootstartdate":"20201126 12:30",
      "shootenddate":"20201126 13:00",
      "shootdate":"20201126",
      "views":"16",
      "rating":"5",
      "project":"59351",
      "project_theme":[54282],
      "theme":[54282,
        758,
        765,
        801,
        756,
        54282,
        825],
      "thesgen_json":[{"id":344,"value":{"DE":"Wettbewerb","EN":"Competition","FR":"Concurrence"}}],
      "thes_gen":[344],
      "location_json":[{"id":73,"value":{"DE":"Brüssel - EK\/Berlaymont","EN":"Brussels - EC\/Berlaymont","FR":"Bruxelles - CE\/Berlaymont"}}],
      "thes_loc":[73],
      "pers_json":[{"preferedterm":"Vestager, Margrethe","id":3473,"value":["Vestager, Margrethe"]}],
      "dg_json":{"shortcut":"COMM","id":404,"titles":{"DE":"Generaldirektion für Kommunikation","EN":"Directorate-General for Communication","FR":"Direction générale de la communication"}},
      "dg":404,
      "cooperator_json":{"AGENCY":{"DE":{"coop":[" Yügen"],"title":"Agentur"},"EN":{"coop":[" Yügen"],"title":"Agency"},"FR":{"coop":[" Yügen"],"title":"Agence"}},"PRODUCER":{"DE":{"coop":[" Europäische Kommission - Audiovisueller Dienst"],"title":"Produzent"},"EN":{"coop":[" EC - Audiovisual Service"],"title":"Producer"},"FR":{"coop":[" CE - Service audiovisuel"],"title":"Producteur"}},"PHOTOGRAPHER":{"DE":{"coop":["Dati Bendo"],"title":"Fotograf"},"EN":{"coop":["Dati Bendo"],"title":"Photographer"},"FR":{"coop":["Dati Bendo"],"title":"Photographe"}}},
      "media_json":{"HIGH":{"PATH":"store2\/1\/P047441-61817.jpg","PIXL":4000,"PIXH":2662},"LOW":{"PATH":"store2\/1\/P047441-365941.jpg","PIXL":200,"PIXH":133},"MED":{"PATH":"store2\/1\/P047441-551709.jpg","PIXL":640,"PIXH":425}},
      "hasMedia":"1",
      "_version_":1684775880224669696,
      "popularity":0,
      "timestamp":"2020-11-30T09:11:25.871Z",
      "parent":{"ref":"P-047441\/00-10","group_media_json":{"id_5885":"75896","text_5885":{"legend":{"EN":"","FR":""},"description":{"EN":"","FR":""},"title":{"EN":"Press conference of Margrethe Vestager, Executive Vice-President of the European Commission, on an antitrust case: Commission fines Teva and Cephalon \u20AC60.5 million for delaying entry of cheaper generic medicine","FR":"Conférence de presse de Margrethe Vestager, vice-présidente exécutive de la Commission européenne, sur un cas de pratique anti-concurrentielle : CE inflige des amendes de \u20AC60.5 millions à Teva et à Cephalon pour avoir retardé l&#39;entrée sur le marché d&#39;un médicament générique moins cher"}},"ids":[5885],"order_5885":"4"},"media_json":{"HIGH":{"PATH":"store2\/1\/P047441-406134.jpg","PIXL":4000,"PIXH":2662},"LOW":{"PATH":"store2\/1\/P047441-608006.jpg","PIXL":200,"PIXH":133},"MED":{"PATH":"store2\/1\/P047441-513898.jpg","PIXL":640,"PIXH":425}},"hasMedia":"1","id":76237280,"summary_json":{"EN":"<p>On 26 November 2020, Margrethe Vestager, Executive Vice-President of the European Commission in charge of Europe fit for the Digital Age, and Commissioner for Competition, gave a press conference on an antitrust case.  <\/p><p>The European Commission has fined the pharmaceutical companies Teva and Cephalon \u20AC60.5 million for agreeing to delay for several years the market entry of a cheaper generic version of Cephalon&#39;s drug for sleep disorders, modafinil, after Cephalon&#39;s main patents had expired. The agreement was concluded well before Cephalon became a subsidiary of Teva. The agreement violated EU antitrust rules and caused substantial harm to EU patients and healthcare systems by keeping prices high for modafinil.<\/p>","FR":"<p>Le 26 novembre 2020, Margrethe Vestager, vice-présidente exécutive de la Commission européenne chargée d&#39;une Europe adaptée à l&#39;ère du numérique, et commissaire à la Concurrence, a donné une conférence de presse sur un cas de pratique anti-concurrentielle.<\/p><p>La Commission européenne a infligé des amendes de 60.5 millions d&#39;euros aux entreprises pharmaceutiques Teva et Cephalon pour s&#39;être mises d&#39;accord pour retarder l&#39;entrée sur le marché d&#39;une version générique moins chère du médicament de Cephalon traitant les troubles du sommeil, le modafinil, après l&#39;expiration des principaux brevets de Cephalon. L&#39;accord a été conclu bien avant que Cephalon ne devienne une filiale de Teva. L&#39;accord a violé les règles de l&#39;UE en matière d&#39;ententes et d&#39;abus de position dominante et a causé un préjudice considérable aux patients et aux systèmes de soins de santé de l&#39;UE en maintenant les prix élevés pour le modafinil.<\/p>"},"titles_json":{"EN":"Press conference of Margrethe Vestager, Executive Vice-President of the European Commission, on an antitrust case: Commission fined Teva and Cephalon for delaying entry of cheaper generic medicine","FR":"Conférence de presse de Margrethe Vestager, vice-présidente exécutive de la Commission européenne, sur un cas de pratique anti-concurrentielle : la Commission a infligé des amendes à Teva et à Cephalon pour avoir retardé l&#39;entrée sur le marché d&#39;un médicament générique moins cher"},"type":"REPORTAGE","primary_key":"P-047441"}}]
  }}
